Actavis Confirms Generic Butrans® Patent Challenge (Actavis Inc)

(Source: Actavis Inc) DUBLIN, Sept. 25, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Buprenorphine Transdermal System, 5 mcg/hr, 10 mcg/hr and 20 mcg/hr.  Actavis' ANDA product is a generic version of Purdue Pharma's Butrans®, which is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative treatment options are inadequate. Logo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO Purdue Pharma L.P. filed suit against Actavis on September...